Literature DB >> 32986234

Performance of the RABBIT infection risk score in an Argentinian rheumatoid arthritis cohort.

Rodrigo N Garcia Salinas1, Maria A Lázaro2, Santiago Scarafia2, Alejandra Cusa2, Maria V Martire3, Nieves Capozzi4, Luciana Casalla4, Lucía Zárate4, María De la Vega5, Maria Correa6, Gustavo C Casado7, Silvia Papasidero8, Silvana Perez8, Oscar L Rillo9, Damaris Alvarez10, Mariana Benegas11, María P Girard Bosch3, Karin Kirmayr12, Ramiro Gomez13.   

Abstract

Patients with rheumatic autoimmune diseases have a higher risk of infections compared with age-and sex-matched controls. In Latin America, there are no validated tools to assess the risk of serious infection. The objectives were to estimate the incidence of serious infections in a cohort of rheumatoid arthritis (RA) patients followed for 12 months and to validate the RABBIT risk score for serious infections. Patients with RA were included and followed for 12 months. Baseline sociodemographic data, comorbidities, RA characteristics, and vaccination status were recorded. The baseline RABBIT risk score was calculated. Serious infections were documented, describing site and time since enrollment. Six hundred five patients were included (13 centers). The incidence of serious infection was 5% (95% CI 3-7). The most frequent sites were respiratory and urinary (90%). Performance of RABBIT risk score: patients with no infection during follow-up had a median score of 1.2 (IQR 0.8-2.1) and patients with infection 5.1 (IQR 2.15-12.6) p 0.00001. ROC curve analysis: AUC 0.86 (95% CI 0.8-0.94), best cut-off 2.85 (sensibility 75%, specificity 85%). The incidence of serious infections was 5% during the follow-up. The RABBIT score performed excellently in our patients. Key Points • The RABBIT risk score for serious infections showed an excellent performance in a population different (Latin America) from the original one included in the German registry. • This may assist rheumatologists in selecting drugs for patients according to the individual risk of infection, in a fast and simple way.

Entities:  

Keywords:  Biological products; DMARD; Glucocorticoid; Infections; Rheumatoid arthritis

Mesh:

Substances:

Year:  2020        PMID: 32986234     DOI: 10.1007/s10067-020-05425-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  2 in total

1.  Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study.

Authors:  Christos E Lampropoulos; Philippos Orfanos; Vasiliki-Kalliopi Bournia; Theofilos Karatsourakis; Clio Mavragani; Dimitrios Pikazis; Menelaos N Manoussakis; Athanasios G Tzioufas; Haralampos M Moutsopoulos; Panayiotis G Vlachoyiannopoulos
Journal:  Clin Exp Rheumatol       Date:  2015-02-09       Impact factor: 4.473

2.  Sustained moderate-to-high disease activity and higher Charlson score are predictors of incidental serious infection events in RA patients treated with conventional disease-modifying anti-rheumatic drugs: a cohort study in the treat-to-target era.

Authors:  Gretel Galicia-Hernández; Federico Parra-Salcedo; Paulina Ugarte-Martínez; Irazú Contreras-Yáñez; Alfredo Ponce-de-León; Virginia Pascual-Ramos
Journal:  Clin Exp Rheumatol       Date:  2016-03-03       Impact factor: 4.473

  2 in total
  1 in total

Review 1.  [Latest findings from the RABBIT register].

Authors:  Yvette Meißner; Anja Strangfeld
Journal:  Z Rheumatol       Date:  2021-12-23       Impact factor: 1.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.